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While pharmacist-provided clinical services in the outpatient setting have 
demonstrated improved clinical, economic, and humanistic outcomes, little is known 
about patients‟ attitudes and perceptions regarding participation in these services. The 
purpose of this thesis was to qualitatively characterize patient attitudes and expectations 
of pharmacist-provided clinical services in the outpatient setting.  
This thesis was conducted within the Intermountain Healthcare system. 
Intermountain Healthcare is a large, integrated healthcare delivery system in Utah and 
Idaho that consists of 22 hospitals, 160 primary- and specialty-care clinics, home-
healthcare services, and 25 hospital- and clinic-based community pharmacies.  
Study participants were identified using the Intermountain Healthcare system-
wide Enterprise Data Warehouse. Participants were included in the study if they had been 
prescribed at least four chronic medications. Participants were excluded if they did not 
speak English or if they could not travel to Intermountain Medical Center. 
The first phase of this study consisted of telephone interviews of approximately 
25 participants. Participants were asked to describe their current relationship with their 
pharmacist and physician and describe their level of trust in engaging their pharmacist in 
their overall healthcare. The second phase consisted of four focus group sessions. Focus 





surveys, as well as react to brief presentations on medication therapy management and 
collaborative drug therapy management.  
Participants recognized pharmacists as medication experts, yet they did not 
currently maintain strong relationships with their pharmacists. Participants perceived that 
these were caused by poor communication between their providers, their pharmacist, and 
their payers. When asked to react to the concepts of medication therapy management and 
collaborative drug therapy management, participants agreed that it should be supported. 
Concerns related to the security of private information were expressed. Questions 
regarding how this service would be perceived by physicians were raised. For example, 
participants were concerned that their physicians would feel as though the pharmacist 
was „stepping on his/her toes‟.  
In conclusion, participants would likely be participatory in pharmacist-provided 
clinical services in the outpatient setting. The design and implementation of these 
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 Adverse events related to medication therapy have a significant impact on the 
healthcare system. As the prevalence of chronic disease continues to increase and 
medication therapy regimens become increasingly complex, efforts to address this 
growing problem are important. Pharmacists in the outpatient setting are uniquely 
positioned and qualified to address this challenge, yet engaging patients with their 
pharmacists in this way is a relatively new concept in the profession of pharmacy.  
 As the provision of pharmacist-provided clinical services in the outpatient setting 
evolves, it is necessary to address the attitudes and concerns of all parties who may be 
impacted by the provision of clinical services, especially given that this movement has 
been primarily driven by the profession of pharmacy. It is important to understand the 
attitudes and expectations of pharmacists, physicians, healthcare payers, and patients in 
order to design programs that meet the needs of all parties. The literature is replete with 
examples of how clinical services result in improved clinical and economic outcomes. 
However, less data are available that characterize patients attitudes and perceptions of 
clinical services. Because active engagement by patients is essential to the success of 





understand patient motivators, concerns, and current challenges related to medication 
therapy.  
 The purpose of this thesis is to conduct a qualitative analysis of patient attitudes 
and expectations of pharmacist-provided clinical services in the outpatient setting. 
Results of this study will add to the current body of knowledge related to these services, 
and may be used to inform the design of pharmacist-provided clinical services in the 
future. 












REVIEW OF THE LITERATURE 
Introduction 
Healthcare expenditures continue to increase in the United States (US), and it has 
become evident to all stakeholders that our current healthcare delivery systems must 
evolve in order to assure sustainability.
1
 Additionally, the proportion of patients with 
chronic disease states who require complex medication regimens is growing.
1
 Many 
chronic illnesses and medical conditions require multiple medications, which can be quite 
expensive and complex.  As such, the need for targeted medication therapy management 
becomes evident. As medication therapy experts, pharmacists are uniquely qualified to 
assist in the design, monitoring, and maintenance of therapeutic plans that include 
medications. Pharmacists have been trained and are uniquely qualified to perform these 
services and assist patients in managing their medications.  
Pharmacy services have been integrated into various patient care delivery settings. 
Pharmacists‟ roles have been justified using cost savings, cost-avoidance, avoidance of 
adverse events, and improved clinical outcomes.
2-4
 In the outpatient pharmacy setting, 
pharmacist-provided clinical services have been shown to positively impact clinical, 
economic, and productivity-related outcomes. 
2,5,6
 A growing body of literature is 





consensus exists within the profession of pharmacy regarding the best business and 
delivery model, marketing strategies, or patient-perceived need for these services. In 
order to appreciate the evolution of pharmacist-provided clinical services, it is necessary 
to understand the history of pharmacist-provided clinical services over the last thirty to 
forty years. A brief review of the evolution of pharmacist-provided clinical services 
includes major legislative initiatives and professional advancements. A review of 
common terminology used to describe these services will also be outlined. 
Evolution of Pharmacist-Provided Clinical Services 
The genesis of contemporary pharmacist-provided clinical services came about in 
the latter part of the 20
th
 century. Prior to the 1950s, pharmacists were often taught not to 
discuss the properties or effects of medications they dispensed to patients.
5
 As 
medications became more complex and the overall model of healthcare provision 
evolved, opportunities emerged for pharmacists to perform services such as patient 
counseling, therapeutic design, and drug monitoring. In 1975, the term „pharmaceutical 
care‟ was first used to describe care that was intended to ensure safe and rational drug 
usage.
7
 Since that time, the concept of involving pharmacists in the design, education, 
monitoring, and adjustment of medication regimens has grown and evolved substantially. 
 Healthcare stakeholders have since recognized the value of these services, and as 
such, have incorporated pharmacists into many care delivery models in a variety of 
healthcare settings.
8
 Evidence of the growing role of these services is the Center for 
Medicare and Medicaid Services, (CMS) decision to require a pharmacotherapy specialist 







 Additionally, guidelines published by the Infectious Disease Society of America 
and Society for Healthcare Epidemiology of America recognize the important role that 
pharmacists play in preventing antimicrobial resistance.
10
 
 As the value of pharmacist-provided clinical services has become more 
recognized and the need for these services has increased, pharmacy practice laws have 
evolved to incorporate the evolving standards of pharmacy practice.  Two key pieces of 
legislation that acknowledged the value of patient counseling and created opportunities 
for pharmacists to receive payment for these services will be described.  
Major Legislation 
The Omnibus Budget Reconciliation Act of 1990 (OBRA 90) was the first 
successful legislative effort to influence the level of clinical service that patients received 
from their pharmacist.
5 
The passage of OBRA 90 required pharmacists to perform drug 
use reviews and to at least offer to discuss medications with patients prior to dispensing.
5
 
Based on the pharmacist‟s professional judgment, pharmacists should discuss issues 
related to patients‟ prescribed therapy, including:  
 Name and description of medication 
 Dosage form, route, and duration of therapy 
 Special directions and precautions in the preparation, administration, and 
use by the patient 
 Common severe adverse effects, interactions, and contraindications 
 Techniques for self-monitoring therapy 





 Prescription refill information, and 
 Action to be taken in the event of a missed dose 
While OBRA 90 describes key components of patient counseling that may be 
incorporated into the pharmacist-patient interaction, it does not mandate that every 
patient receive every point of information. The legislation supports the professional 
judgment and autonomy of the dispensing pharmacist, and allows pharmacists to tailor 
the interaction based on the needs and desires of the individual patient. Prior to the 
passage and implementation of OBRA 90, all federal regulations related to pharmacy 
addressed the integrity of drug products, including handling of controlled substances and 
other drug distribution activities.
4
 OBRA 90 acknowledged a public expectation that 




The expectation that pharmacists should be engaged in the management of drug 
therapies was further defined with the passage of the Medicare Modernization Act of 
2003 (MMA). MMA represented the most significant change to Medicare benefits since 
Medicare‟s inception in 1965.5 A major provision of MMA was establishment of a 
prescription drug benefit for Medicare beneficiaries. In addition, MMA mandated 
coverage, and provided reimbursement for, medication therapy management (MTM) 
activities. While MMA states that MTM services can be performed by a number of 
healthcare professionals including physicians and nurses, pharmacists were specifically 
stated as a healthcare professional qualified to perform and bill for MTM services.  
 MMA went into effect in January of 2006,
5
 and since then, outpatient pharmacists 





medication dispensing-based business model. Because the provision of these services is 
still very much in its infancy, operational challenges have been a significant barrier to 
their implementation. Effective business and staffing models, marketing strategies, 
documentation methods, and billing tools have yet to be fully elucidated. Recognizing 
this need, pharmacy‟s professional societies have engaged multiple healthcare 
stakeholders, including patients, payers, and providers, to determine the priorities and 
necessary steps to standardize the billing and documentation expectations for MTM.
11
  
As movements created the expectation for pharmacists to be more engaged in the 
delivery of patient care, a need arose for demonstrated improved outcomes as a result of 
pharmacist-provided services. Since then, a number studies designed to demonstrate 
clinical value have been published in professional literature. Most studies that have 
explored pharmacist-provided clinical services in the outpatient setting have included 
measurement of both clinical and economic outcomes in their analysis.
 6,12,13
 More recent 
studies have also included patient satisfaction outcomes.
14,15
 Major outcomes in these 
bodies of literature can be grouped into the following primary areas: 
 Impact on clinical outcomes 
 Impact on economic outcomes, and 
 Patient perceptions and attitudes 
Each of these areas represents a unique and important outcome measure that is important 






Impact of Pharmacist-Provided Clinical Services on Clinical Outcomes 
Four major studies have been conducted to evaluate the impact of pharmacist-
provided clinical services on patient clinical outcomes. These services were provided in 
the outpatient setting with varying levels of integration with other healthcare services 
such as physician-provided primary and specialty care. However, these studies 
consistently designed pharmacist-provided clinical services to meet the needs of patients 
who had chronic illnesses or were on multiple chronic medications.  
The Asheville Project 
One of the most notable studies that evaluated the value of pharmacist-provided 
services in outpatient pharmacies was the Asheville Project.
12
 Conducted in Asheville, 
North Carolina, this study evaluated both the clinical and economic outcomes of 
medication therapy management (MTM) services in patients with hypertension and/or 
dyslipidemia. Over a 6-year period in 12 community pharmacies, patients in participating 
health insurance plans were eligible to enroll if they had a diagnosis of hypertension 
and/or dyslipidemia, regardless of baseline control. Once enrolled, patients were assigned 
to a specific pharmacist who acted as their care manager for the duration of the study. 
The unique components of the program included: 
 self-care education provided by professional educators (non-pharmacists) 
 face-to-face consultation performed by community and hospital 
pharmacists, and 
 financial incentives, offered by the patient‟s payer, to encourage patient 





Participants met with their assigned pharmacist up to once monthly during the 
study period to receive focused education and planning. Sessions averaged 30 minutes in 
duration, and took place every 3 months on average. Treatment goals for lipid 
management were assigned based upon the Adult Treatment Panel III (ATP III)
12,16
 and, 
for blood pressure management, the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII).
12,17
 
Goals were communicated to patients at each session.  
Clinical outcomes of interest in The Asheville Project were blood pressure, low-
density lipoprotein (LDL) levels, total cholesterol levels, serum triglyceride levels, and 
high-density lipoprotein (HDL) levels. The percentage of patients who reached their 
assigned goals for these levels was assessed, as well as absolute changes in serum lipids 
and blood pressure. Additionally, the number of cardiovascular events (e.g., acute 
myocardial infarction, cardiac death) that took place during the study period was 
analyzed.  
The proportion of patients who achieved their LDL goals increased from 49.9% to 
74.6% during the study period. The proportion of patients who achieved their total 
cholesterol and triglyceride goals also increased significantly, although no statistical 
improvement was seen in HDL levels throughout the study period. Blood pressure 
management improved throughout the study period. The proportion of patients who 
achieved their blood pressure goals increased from 40.2% to 67.4% (p <0.0005). 
Additionally, the proportion of patients diagnosed with Stage I hypertension and Stage II 





The number and severity of cardiovascular events decreased significantly during 
the study period, as compared with a historical reference period of two years prior to 
enrollment. Based on incidence rates prior to the study period, investigators expected that 
98 cardiovascular events would occur. However, only 48 events occurred during the 




The investigators concluded that a community-based cardiovascular disease 
management program that provided face-to-face counseling by community pharmacists 
resulted in significantly improved clinical outcomes. The Asheville Project was 
conducted without randomization or a control group, which may have confounded the 
results. Another limitation of this study was that patients were recruited from two self-
insured health plans in Asheville, North Carolina. However, the Asheville Project was the 
first of its kind to show both clinical and economic benefits from community pharmacist 
intervention. Other studies have explored the effects of the interventions used in The 
Asheville Project in more diverse patient populations.
18
 One example is described below. 
Diabetes Ten City Challenge 
Collaboration between the American Pharmacists Association and 
GlaxoSmithKline allowed for the launch of the Diabetes Ten City Challenge.
18
 The 
purpose of this study was to expand on the care process model used in the Asheville 
Project, and apply the same study methods to a different disease state in various locations 
throughout the US. This program was offered as a voluntary employer benefit at ten 





pharmacies, ambulatory care clinics, and on-site work locations. A collaborative care 
model was used between the employer, physician, pharmacist, and patient. Financial 
incentives were created for both patients and pharmacists who participated. Patient-
centered incentives included waived co-payments for medications and laboratory tests. 
Pharmacists received reimbursement for time spent in patient visits, and were also 
required to communicate with each patient‟s physician after each visit regarding patient 
status. Patients attended regularly scheduled visits with their pharmacist, which included 
clinical assessments and progress toward clinical goals. Goals were assigned based upon 
current American Diabetes Association (ADA) recommendations. Pharmacists ordered 
and analyzed laboratory testing as necessary.  
Clinical outcomes of interest included glycosylated hemoglobin (Ha1c) levels, 
LDL cholesterol levels, blood pressure, and body mass index. Additional outcomes 
included the proportion of patients with current records for influenza vaccines, foot 
examinations, and eye examinations, which reflected the current practice 
recommendations of the ADA at the time of the study. Healthcare Effectiveness Data and 
Information Set (HEDIS) process measures for diabetes management were also collected 
and evaluated.
19,20
  Finally, patient satisfaction regarding services received was also 
assessed.  
Patients enrolled in The Diabetes Ten City Challenge showed statistically 
significant improvements in Ha1c, cholesterol, and blood pressure measurements after 
one year. Glycosylated hemoglobin values decreased on average from 7.5% to 7.1% (p = 
0.002) during the study period. The proportion of patients who achieved Ha1c goals 





decreased from 96.3mg/dL to 93.3mg/dL (p <0.001), with a 13.9% increase in the 
proportion of patients who reached goal during the study period. The proportion of 
patients who maintained current influenza vaccinations also increased from 43% to 61% 
during the study period. The proportion of patients who were current relative to eye 
examinations increased from 60% to 77% during this period, while the proportion of 
patients who were up-to-date with foot examinations also increased from 38% to 68%.
14
 
Investigators concluded that a pharmacist-driven collaborative-care model had the 
potential to improve clinical outcomes in a clinically meaningful manner. Therefore, this 
model may aid in the transformation of how the healthcare system manages patients with 
diabetes.  
North Carolina State Health Plan (SHP) 
The North Carolina State Health Plan (SHP) assessed the feasibility of conducting 
an MTM-type program in a large and stable population, which consisted of the SHP 
employee-base. In this demonstration project, a pharmacist-provided MTM service pilot 
project was conducted between October of 2004 and March of 2005, as a voluntary, no 
cost service to state health plan members.
21
  The objectives of this study were to describe 
potential drug therapy problems that could be identified by pharmacists, identify services 
performed for resolution of those problems, and measure clinical outcomes in terms of 
changes in drug therapy and subsequent medication use. This voluntary program was 
designed to target patients who used a large number of prescription medications, and 





In order to recruit patients, letters were sent to 1,000 state health plan patients 
who received the highest number of prescriptions during the first 6 months of 2004. The 
first 130 responding patients were then offered an MTM session at no cost to them. Of 
these 130 patients, approximately 80 visits were conducted. A total of 236 drug-related 
problems were identified by pharmacists, representing a mean of 3.6 problems per 
patient. The most common problems included potential under-use, potential over-use, 
suboptimal drug selection, and the presence of another more cost-effective option. A 
change to improve drug therapy was made in about 50% of the problems identified by the 
pharmacist.  
The authors of this study concluded that pharmacist-provided MTM was 
successful in both identifying drug-related problems and effecting changes in drug 
therapy regimens that were designed to improve patient care. Additionally, pharmacists 
were able to educate patients about their disease states, self-management principles, and 
the importance of medication adherence. This study demonstrated that pharmacists‟ 
independent review of medications with patients can result in identification of potential 
problems and changes to therapeutic regimens.  
Fairview Health Services 
Pharmacists in a group of university-associated ambulatory care clinics conducted 
this study to assess the clinical impact of pharmacist-provided MTM on clinical outcomes 
and HEDIS-related outcomes in patients with one of 12 identified medical conditions.
13
 





hyperlipidemia who received free MTM were compared to a matched-population who did 
not receive MTM services over one year.   
Patients recruited from a single insurance entity were already enrolled as patients 
at one of six Fairview Health Services clinics in which MTM services were provided. 
Study patients also had two or more healthcare claims related to their study condition in 
the 6 months preceding the enrollment period.
13
  
Three clinical outcomes were measured:  
 goals of therapy achieved 
 number of drug therapy problems resolved, and  
 status on selected HEDIS measurements 
A total of 637 drug therapy problems were identified by pharmacists during the 
study period. Of those, approximately 78% were resolved without direct contact with the 
physician. The proportion of patients whose therapeutic goals were being met, as defined 
by the patient, increased from 76% to 90% during the study period.  
Regarding HEDIS measures, approximately 71% of intervention patients and 59% 
of control group patients met the HEDIS standard for hypertension management (p = 
0.03).  Approximately 52% of intervention patients and 30% of control group patients 
met the HEDIS standard for cholesterol management (p ≤ 0.001). Investigators concluded 
that study results supported a growing body of evidence demonstrating improved clinical 
outcomes that are associated with pharmacist-provided MTM services.  
While evidence exists to suggest that the inclusion of pharmacists in the design, 
monitoring, and maintenance of medication therapy regimens improves clinical 





Several studies designed to assess clinical outcomes associated with pharmacist-provided 




Impact of Pharmacist-Provided Clinical Services on Economic Outcomes 
While pharmacists have employed their clinical knowledge and skills to improve 
patient outcomes for a number of years, it was not until the mid-1990s that a movement 
was formalized to advocate for pharmacists to be able to be paid for their time spent 
engaged in these activities. It is evident that if pharmacist-provided clinical services are 
to be reimbursed by payers, the profession of pharmacy will need to demonstrate both 
clinical and economic benefit from these services to patients. Data regarding the 
economic viability of clinical services will also assist in the development of payment 
models for these services in the future. Economic indicators including medication-related 
costs, non-medication-related costs, and total healthcare expenditures have been used to 
assess the economic impact of pharmacist-provided clinical services. Most of the large 
studies that were designed to explore the clinical outcomes of pharmacist-provided 
clinical services also included economic evaluations, as described below. 
The Asheville Project 
The Asheville Project
8
 explored economic outcomes that included direct 
cardiovascular medical costs, medication costs, and the costs of the program itself. Per-
person-per-year cardiovascular healthcare expenditures decreased from an average of 





during the study period, this was offset by a decrease in overall healthcare expenditures. 
Overall, cardiovascular-related spending decreased from 30.6% of overall spending to 
19.6% during the study period, which was attributable to fewer medical events.  
Additionally, the cost of cardiovascular-related events prior to the initiation of this 
study was $14,343 per event. During the study period, the cost decreased to $9,931 per 
event. In the population studied, this resulted in a reduction of $928,926 related to 
averted cardiovascular-related costs. These data demonstrated that the Asheville model 
has the potential to improve both clinical and economic outcomes. While the Asheville 
model was associated with overall healthcare savings, further exploration of the 
economic benefit of pharmacist-provided clinical services, especially using other clinical 
models, is warranted.  
Fairview Health Services 
The MTM project conducted within the Fairview Clinics in Minnesota also 
assessed economic outcomes using the Blue Cross Blue Shield of Minnesota (BCBSM) 
medical claims database and the Prime Therapeutics LLC database.
13
 Total healthcare 
expenditures were measured in the year preceding the study year, and the costs of 
providing MTM services were calculated in aggregate. In the year preceding the study, 
total health expenditures were estimated at $11,965. This annual amount was reduced by 
31.5% to $8,197 during the study period (p ≤ 0.0001). Prescription drug expenditures 
increased by 19.7% during the study period (not statistically significant), but represented 
increased utilization of medications. Overall, medication-related expenditure increases 





The cost of providing these services was estimated to be approximately $239.40 
per patient per year. When the cost of handling and processing the additional claims was 
added, the total cost of providing these services (provider and payer) was estimated to be 
$266.08 per person per year. The investigators concluded that the cost savings realized by 
reduced facility and professional fees was sufficient to justify the sustainment of this 
program.  
Like the study conducted within the Fairview Health System, most studies that 
have assessed the impact of pharmacist-provided clinical services have measured single 
programs or networks of similar programs. One analysis attempted to characterize these 
outcomes across a large span of MTM programs and services. This was conducted by a 
corporation that manages documentation and billing software.  
Mirixa Corporation 
Economic analyses have also been conducted to assess the impact of MTM on 
Medicare Part D prescription drug costs, use, and generic dispensing ratio. An analysis 
was conducted in health plan clients of the Mirixa Corporation, which provides a 
documentation and billing platform for MTM services.
6
 This analysis compared three 
MTM modalities: community pharmacy-based, pharmacist-staffed call center-based, and 
educational mailings. Outcomes of interest were analyzed using claims data, health plan 
enrollment data, vital statistics, and the MTM databases for each health plan.  
Among the 1.2 million Medicare Part D beneficiaries enrolled in health plans who 
contracted with Mirixa, approximately 101,846 met eligibility criteria for MTM. Of 





12,196 by phone, 49,021 by mailing). During the 2-year study period, patients receiving 
an MTM service showed a decline in monthly drug costs of $35 (from $669 to $634). 
Mean monthly prescription counts decreased by 5% ($9.79 to $9.29) in patients who 
received face-to-face MTM versus 1.3% for call-center patients, and decreased by 1.8% 
for patients who received MTM mailings. The weighted generic dispensing ratio 
increased by 9.4% in the face-to-face group, 10.2% in the call-center group, and 8.1% in 
the group that received MTM mailings. The investigators concluded that MTM among 
eligible Medicare Part D recipients decreased overall drug costs and increased the generic 
dispensing ratio.  
While studies that assess the economic impact of pharmacist-provided clinical 
services in the outpatient setting are few, the evidence presented is promising and further 
exploration is warranted. Pharmacist-provided clinical services are provided in a variety 
of clinical settings and use varying patient recruitment techniques, documentation and 
communication strategies, and outcomes measures. Each model of delivery will require 
economic assessment as these services continue to grow and expand.  
Patient Perceptions and Attitudes of Pharmacist-Provided Clinical Services 
While studies that demonstrate the clinical and economic benefit of pharmacist-
provided clinical services in the outpatient arena are widely available, only a small 
number of investigators have explored the impact of pharmacist-provided services on 
patient satisfaction. An even a smaller number have explored patients‟ attitudes and 





body of knowledge has not included patient attitudes regarding MTM or patient 
satisfaction with MTM as major endpoints. 
The Fairview Health Clinics project conducted by Isetts et al.,
13
 clearly 
demonstrated both clinical and economic benefit; however, no analysis of patient 
satisfaction or perceptions was conducted. Additionally, in the hypertension and 
hyperlipidemia arm of The Asheville Project,
12
 no assessment of overall patient 
satisfaction or willingness to self-refer into the program was conducted.  
 Most of the data currently available to answer this question has been captured as 
an outcome of a program that also explored clinical and economic outcomes. Patient 
satisfaction and perceptions of care are often only assessed after patients have received 
these services. The major contributions to this body of knowledge are described below. 
Diabetes Ten City Challenge 
In addition to assessing clinical outcomes, the Diabetes Ten City Challenge 
explored the impact of a collaborative care model on patient satisfaction.
18
 Surveys were 
administered to enrolled patients at baseline and prespecified follow-up times, 
approximately 1-year after enrollment. Participants were asked to rate their overall 
satisfaction with their diabetes care on a scale of one to ten (one being worst possible 
care, ten being best possible care). Patient satisfaction with their pharmacist was assessed 
using a 5-point Likert-type scale. A total of 764 surveys were completed at baseline, and 
224 surveys were completed after 1-year of enrollment.  
During the study period, the proportion of patients who ranked their overall 





patients reported being either “very satisfied” or “satisfied” with the diabetes care 
provided by their pharmacist. The investigators concluded that the collaborative care 
model described in this study not only improved clinical indicators, it also enhanced 
patient satisfaction as well. This study is unique in that it assessed patient satisfaction 
with pharmacist-provided clinical services related to the management of diabetes over 
multiple geographic areas and both before and after enrollment in the study. After 
receiving care provided by pharmacists, patients indicated an increase in satisfaction; 
however, no data was collected that assessed whether patients would self-refer into this 
type of care process model if the other financial incentives were not provided.  
University of Minnesota College of Pharmacy 
Isetts et al.
15
 examined the effect of pharmacist-provided collaborative drug 
therapy management on patient perceptions of care and health-related quality of life. This 
study was conducted in 199 patients who received collaborative drug therapy 
management (CDTM) as compared to 159 patients who did not receive CDTM (usual 
care). CDTM services were provided in 15 ambulatory care clinics in the state of 
Minnesota during a 12-month period. Two standardized assessment tools, including the 
Consumer Assessment of Healthcare Providers and Systems (CAHPS®) and The Short 
Form-12, were administered to CDTM patients enrolled in MTM programs and patients 
who received usual care.
22,23
 The CAHPS® survey was developed through the US 
Department of Health and Human Services as a tool to measure consumers‟ healthcare 
experiences. The Short Form-12 is a standardized survey tool designed to assess health-





No statistically significant differences in CAHPS® scores were seen between 
patients who received CDTM and those who did not. However, a trend toward 
improvement was seen. Statistically significant differences were seen between groups 
using the Short Form-12 survey. While this study was one of the first in the literature to 
assess the impact of pharmacist-provided clinical services on patient satisfaction and 
health-related quality of life, use of a broad assessment tool that only measured the global 
patient experience limited applicability.  
Assessing Perceptions of MTM among Medicare Part D Recipients 
Truong et al.
24
 assessed patient perceptions of MTM services among Medicare 
Part D recipients. The objective of this study was to characterize patients‟ perceptions 
and expectations about MTM services pertaining to the core elements of an MTM service 
in the community pharmacy setting. Using a cross-sectional design, a 14-question survey 
was administered to 81 Medicare Part D recipients. Likert scale questions and open-
ended questions were used in the survey, as well as basic demographic questions. This 
survey was tested in a pilot group for validation prior to being administered to study 
patients. Of the 250 surveys administered, 81 were returned, yielding a response rate of 
32%. Analysis of the demographic characteristics of the study population indicated that 
approximately half of the responding patients had either multiple chronic diseases or 
were taking five or more medications. Approximately 25% of respondents expected to 
spend at least $4000 on prescriptions in 2006.  
The majority of responding patients had never heard of MTM services. When the 





approximately 70% of surveyed patients felt as though they were important or very 
important. Patients indicated that they would prefer to learn about these services using 
paper brochures, as well as receive an introduction to these services given by their 
pharmacist.  
Investigators of this study concluded that patients had very little knowledge of the 
core elements of an MTM service in the community pharmacy setting. However, patients 
were supportive of these services and felt as though they could improve communication 
and their relationship with their pharmacist. This study is unique in that it only included 
Medicare Part D recipients, the largest population of patients eligible to receive coverage 
for MTM services as part of their prescription benefit.  
Garcia et al. 
25 
conducted a focus-group survey that explored patients‟ reactions to 
information about pharmacist-provided clinical services and MTM. This qualitative study 
was conducted as a series of three semistructured focus group sessions and included a 
total of 26 university employees as participants. Open-ended questions were asked 
regarding medication-related needs, perceived costs and benefits of MTM, and MTM 
marketing strategies. Focus groups were evaluated using qualitative thematic analysis. 
Results revealed that patients would like more information about medications that they 
were taking, and appreciated when pharmacists acted as „problem solvers‟. Some 
participants (percentage not reported by authors) expressed a desire to receive an updated 
list of their medications each time they had a change in their medication regimen. Some 
participants (percentage not reported by authors) expressed concern that their pharmacist 
seemed „too busy‟ to be able to provide MTM services. Additionally, a slide show was 





positively to the outline of these services and felt as though they would like the assurance 
of knowing that they “were doing the right thing” with their medications.  
When asked about how MTM services could be marketed, four main themes in 
patient responses were identified. Patients expressed concerns with using the term 
“Medication Therapy Management”. They indicated that a term such as “Med Check Up” 
or “Med Review” would be more appropriate. Many patients felt they needed to 
experience MTM services before they would be willing to pay for the service or 
recommend it to a friends or family. Last, patients also felt as though marketing materials 
should be made to feel “personal” or should relate to something that they already know. 
Patients suggested that marketing materials should contain personal photos that 
demonstrate warmth on behalf of the provider.  
 This focus group was the first in the literature to describe how patients who have 
never received MTM felt it should be described and marketed. However, it was 
conducted in 26 university employees who were taking at least one chronic medication. 
This represents a fairly narrow subset of the population that could potentially perceive 
benefits from these services. 
Summary 
The development and implementation of pharmacist-provided cognitive services, 
such as MTM, collaborative drug therapy management, and other cognitive services have 
been primarily driven by the profession of pharmacy. As these services become 
integrated into healthcare delivery models and their place in healthcare becomes 





services. While it has been well-documented that pharmacist-provided cognitive services 
have the potential to impact clinical, economic, and humanistic outcomes, studies that 
assess patient satisfaction with these services are not available.  
Pharmacist-provided clinical services have been constructed to include disease-
state management, MTM, immunization services, wellness and preventative medicine, 
and focused patient education. MTM is a broad term that encompasses a host of services 
designed to improve patients‟ understanding of their medications, as well as other clinical 
and economic parameters. Organizations that deliver and pay for these services primarily 
refer patients based upon clinical or economic factors such as the presence of multiple 
chronic disease states, greater than five chronic prescriptions, or annual expense for 
medications that is over a prespecified amount. Despite the growth in pharmacist-
provided clinical service programs, there is there is little evidence to guide pharmacists in 
developing services that meet specific patient-driven needs. 
Community pharmacies struggle to incorporate MTM into their pharmacies for a 
variety of reasons, including lack of documentation and billing tools, and lack of patient 
demand for services. Another major challenge that has been identified by both 
pharmacists and payers is that patients who are offered pharmacist-provided services 
often decline them. While the reasons for slow patient-uptake have not been clearly 
identified, it is evident to all stakeholders that patients may not perceive value in 
pharmacist-provided clinical services when initially offered them. Several studies, 
including the Diabetes Ten City Challenge,
18
 have administered patient satisfaction 
surveys at various points throughout the study period. While patient response to these 





self-refer into these programs. Although there are many other types of pharmacist-
provided clinical services characterized in the literature, little evidence is available to 
suggest that patients perceive enough value in these services to participate voluntarily. 
Additionally, the business model that community pharmacy was built upon relied 
on dispensing fees and margins on the sale of medications and other non-medication 
commodities. As reimbursements are dwindling and mail-order distribution and discount 
prescription formularies are growing, margins are growing smaller. As a result, patient 
retention becomes crucial to the viability of the community pharmacy. Effective 
communication to patients regarding potential benefits of these services could drive 
patient retention and increase compliance with medication regimens.  
Community pharmacies have struggled to adopt new business models that 
incorporate pharmacist-provided clinical services. More information regarding patient 
demand or perception of value related to these types of services could aid community 
pharmacies in their efforts to build services. Rather than developing and implementing 
wholesale practice changes, pharmacists could focus on only those activities that add 
value from the patient‟s perspective in an effort to enhance patient satisfaction and 
improve patient retention.  
Statement of the Problem 
While pharmacist-provided clinical services have demonstrated improved clinical, 
economic, and humanistic outcomes, little is known about how to effectively market and 





Therefore, this thesis will explore patient preferences and reactions to a description of 
potential pharmacist-provided clinical services in the outpatient setting.  
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In order to characterize the attitudes and expectations of patients regarding 
pharmacist-provided clinical services in a clinic-based, community pharmacy setting, 
patients of Intermountain Healthcare outpatient clinics were surveyed regarding their 
attitudes and perceptions of pharmacist-provided clinical services. Qualitative 
methodologies were used in this study, which reflect an inductive, or Grounded Theory, 
approach to analysis.
1
 The results of qualitative research lead to the development of a 
description, characterization, or theory related to the study question. The investigator 
analyzes specific data points to develop a more general theory about the research 
question, as related to the population or phenomenon studied.
2,3 
This study design was selected to explore patient attitudes and expectations 
regarding pharmacist-provided clinical services without imposing pre-conceived ideals or 
assumptions onto the population. The assumption in using this design is that patient 
attitudes and expectations related to their healthcare, and specifically, their pharmacy 
experience, contribute to their decision-making. Therefore, it is important to fully 
elucidate and understand patients‟ attitudes when designing and implementing effective 





In collaboration with the Intermountain Healthcare Office of Research, the 
Department of Pharmacy Services conducted a qualitative analysis to assess patient 
attitudes and expectations of pharmacist-provided clinical services, using semi-structured 
telephone interviews and focus groups. The study was conducted in two phases: 
telephone interviews were conducted initially and focus group sessions were planned to 
confirm and further explore themes and issues identified using data collected in the first 
phase. The scope of this analysis was limited to patients who take multiple medications 
for chronic conditions as they are considered to represent the population of patients for 
whom Intermountain Healthcare department of pharmacy is seeking to target services.  
The first phase of data collection was conducted using a telephone survey that 
was administered by the Intermountain Healthcare Office of Research and Marketing. 
The survey was designed to assess patients‟ current attitudes and expectations of 
pharmacist-provided clinical services as well as their satisfaction with current level of 
understanding regarding their medications. Telephone survey responses were analyzed to 
identify common themes related to patient expectations of current pharmacy services.  
The second phase of data collection was conducted using focus groups. Themes 
identified during the telephone surveys were tested for confirmation using a focus group 
methodology.
4
 Additionally, a description of pharmacist-provided clinical services, with 
examples, was provided to focus group participants. Patients were asked to react to this 
description and indicate their overall impression of this service. Focus group responses 
were analyzed to identify common themes, which were used to characterize overall 







Intermountain Healthcare, founded in 1975, is an integrated healthcare delivery 
system in Utah and Idaho consisting of 22 hospitals, approximately 150 outpatient 
clinics, 25 community pharmacies, home-care services, and a health insurance division.
5
 
The Intermountain Healthcare Department of Pharmacy employs over 300 pharmacists, 
approximately 50 of which practice in clinic-based and hospital-based community 
pharmacies. The Department of Pharmacy offers a variety of clinical pharmacy services 
within the hospitals, and to a limited extent, in the hospital-based clinics.  
The greater Salt Lake Valley is the largest metropolitan area that Intermountain 
Healthcare serves. This geographic region was chosen due to diversity of patient types as 
well as providing a central location to hold the focus group sessions.  
Patient Selection 
Patients were identified using the Intermountain Healthcare Enterprise Data 
Warehouse, specifically the HELP2 prescription database.
6
 The HELP2 database captures 
prescriptions written, but does not capture prescriptions filled at an Intermountain 
Healthcare pharmacy. Therefore, the pharmacy in which patients chose to fill their 
medications was not a factor in patient selection. The HELP2 database was chosen so as 
not to limit the study population to only patients who currently use Intermountain 
Healthcare community pharmacies. If the outpatient pharmacy information system was 
used, it would have only captured patients who currently fill prescriptions at one of these 
pharmacies. In order to obtain a study population that currently utilized a variety of 





database within the clinic health record was utilized. The electronic data warehouse was 
queried to identify a population of patients who met the following inclusion and 
exclusion criteria described below. Prescription information was obtained from the 
Intermountain Healthcare HELP2 prescription database.
6
  
The initial results of this query were sorted by number of unique prescriptions as 
well as by number of refills available. Additionally, American Hospital Formulary 
Service (AHFS)
7
 classifications were used to determine classes of medications prescribed 
in order to ensure that medications prescribed were considered to be “chronic” 
medications. Patients were then sorted by age and city of residence to ensure that the 
potential study population met inclusion and exclusion criteria. The search query was 
limited to patients who had been seen at Intermountain Medical Group Clinics between 
November and December of 2009, in order to create a pool of potential study participants 
who had recently accessed healthcare services at Intermountain Healthcare.  
Patients of an Intermountain Healthcare Medical Group Clinic located within the 
greater Salt Lake Valley, as determined by zip code, were eligible for participation in 
either the telephone call survey or the focus group. Additionally, patients recruited for 
this study were prescribed at least four chronic medications. Patients were required to be 
English-speaking, at least 18 years of age, and willing to participate in the survey in order 
to be included. Non-English speaking patients, patients less than 18 years of age, patients 
taking fewer than four prescriptions, or patients with an address outside of the greater 
Salt Lake Valley area were excluded.  
These criteria were chosen in order to recruit a participant sample representative 





participants may perceive a need for pharmacist-provided clinical services or stand to 
benefit from these services, based on the number of chronic medications prescribed to 
this patient cohort.  
Phase One: Telephone Interviews 
 The first phase of data collection was conducted using a structured telephone 
interview (appendix A). Structured interviews were designed to facilitate focused 
exploration of specific topics rather than to gain insight into social views.
3,4
 Specific 
topics addressed were designed to provide foundational insight and inform the focus 
group sessions that comprised the second phase of this study.   
The interview was administered by Intermountain Healthcare Office of Research 
personnel and was designed to take approximately 10-12 minutes to complete. The 
purpose of the telephone-based interview was to assess patients‟ current attitudes and 
expectations of pharmacist-provided services, as well as their satisfaction with their 
current level of understanding regarding their medications. Further demographic data was 
not collected on this cohort of patients due to limitations in the data collection capacity of 
the Intermountain Healthcare Office of Research.  
Prospective participants were Potential participants were contacted in the evening 
of the week following the mailed letter and asked to participate. Upon being contacted by 
the interviewer, prospective participants were informed of the purpose of the call and the 
purpose of the interview. They were also informed that they were not obligated to 
participate. If they chose to do so, they would receive a gift card in the amount of $10.00 





asked whether they had any questions prior to being asked to give verbal consent to 
participate in the telephone survey.  
 
Data Analysis 
Upon completion of the interviews, data analysis was performed using a grounded 
theory approach.
1,4,8,9
 Transcripts were collated according to question that was asked. The 
investigator and the research associate independently reviewed transcripts for each 
question to identify common phrasing which represent a thought or idea. Each time this 
phrasing or idea appeared, it was be grouped with other instances of its kind. Transcripts 
were reviewed several times as the identification of pertinent phrases or key ideas are 
often iterative.
1
 When all key ideas were identified, the investigators compared and 
contrasted data to create categories, or clusters, of ideas. Idea categories were tested in 
the second phase of this study by asking focus group participants to share their personal 
thoughts or attitudes related to the idea presented by the focus group facilitator.  
Phase II: Focus Groups 
The second phase of the study consisted of focus groups among the same 
population of patients. Focus group sessions were conducted after the telephone interview 
data had been analyzed. Prospective participants were mailed a letter from Intermountain 
Healthcare stating that they had been identified as a potential study participant (appendix 
B). The letter included a brief description of the purpose of the project, as well as a way 
for the potential participant to decline participation. Potential participants were contacted 





by Lighthouse Research, a local market research firm with which Intermountain 
Healthcare contracted to complete this work. The script used to conduct the recruitment 
phone calls was designed to inform potential participants about the purpose of the project 
as well as screen them to ensure that each participant met inclusion and exclusion criteria 
(appendix C). 
Four focus groups were held at Intermountain Medical Center, located at 5121 
South Cottonwood Street, Murray, Utah 84157. All focus groups were held in the 
evening from 7:00pm to 8:30pm due to limitations in scheduling. Each focus group held 
between 8 and 12 participants. Participants were compensated $50.00 cash for their time 
and travel.  
At the beginning of the session, the research coordinator provided an orientation 
to the session, and participants were allowed to ask questions prior to completing the 
consent document and demographic survey (appendix D). Demographic surveys were 
completed by each participant in order to gather information such as current choice of 
pharmacy and type of prescription benefit coverage. These data were collected and 
analyzed concurrently with focus group transcripts in order to group or stratify patient 
responses by demographic factors. The demographic survey was designed to take 
approximately 2 to 3 minutes to complete.  
The focus group facilitator began sessions by asking open-ended questions to 
facilitate participant discussion. Additionally, the facilitator introduced concepts that 
emerged from telephone surveys in order to confirm, and further evaluate, themes that 
had been identified using the telephone surveys. Second, a pharmacist provided a brief 





briefly answered questions about the presentation. In order to minimize the volume of 
information that participants were asked to retain, pharmacist presentations were limited 
to one to two minutes in length. The facilitator then asked questions of the participants. 
The pharmacist presented a total of three models of pharmacist-provided clinical services, 
including medication therapy management, collaborative drug therapy management, and 
patient self-management of medications (appendix E). The information presented by the 
pharmacist was designed to be easily understood, and was delivered using layman‟s 
terms whenever possible.  
Focus group sessions were facilitated by staff of the Intermountain Healthcare 
Office of Research in order to reduce the influence that having a pharmacist in the room 
might have on participant responses. Focus groups followed a semistructured format in as 
much as the facilitator was knowledgeable of the purpose and aim of the focus group, but 
had the latitude to allow the focus group to explore concepts that were introduced by 
participants in the discussion (appendix F).
3,4,8
 Focus group sessions were audio-recorded 
and were reviewed by the pharmacist investigators and the Office of Research staff using 
an inductive, grounded theory methodology.  
 
Data Analysis 
Transcripts from the focus groups were collated by topic. The investigator and a 
research associate independently reviewed transcripts by question and identified common 
phrasing that might represent similar ideas or phrases. Each time similar phrasing or a 
new idea appeared, it was grouped with the other instances of its kind. Transcripts were 







 When all key ideas were identified, investigators compared and contrasted the 
results to create categories, or clusters, of ideas.  
Taxonomy and themes were identified using a grounded theory approach.
1,4,8
 
Pharmacist investigators and office of research staff worked collaboratively to identify 
themes and assign an appropriate taxonomy to participant responses. Once appropriate 
themes were identified, patient perceptions were described in terms of each theme 
identified.  
The institutional review boards of Intermountain Healthcare system wide and the 
University of Utah reviewed and approved this study. 
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Qualitative analysis of a total of 26 telephone interviews and four focus groups (N 
= 38) revealed several themes and concepts that allowed for greater understanding of 
patient attitudes and expectations related to pharmacist-provided clinical services in the 
outpatient setting. Telephone survey participants did not complete every question on the 
survey; therefore certain questions contained fewer than 26 responses. Telephone survey 
data were compiled and assessed prior to focus group sessions, so that any themes 
identified in the telephone survey could be further explored in the focus groups. Focus 
groups further explored themes identified during telephone interviews including the 
concepts of medication therapy management as well as collaborative drug therapy 
management. Additionally, a brief demographic survey was administered to focus group 
participants (appendix D). Results of telephone surveys, demographic surveys, and focus 
groups will be reported and described in terms of general themes identified.  
Telephone Surveys 
Patients were queried in telephone interviews regarding their perceived need for 
improved care and services related to medication therapy. While some variation was 





more information and guidance related to medication therapy. Nineteen of the 26 (73.1%) 
telephone survey respondents felt as though they understood „completely‟ why they were 
taking their medications (Table 1). There was some degree of variability in sources that 
were used to gather information related to medications (Table 2). Sources of medication-
related information included physicians, pharmacists, medication information sheets, and 
to a lesser extent, alternate sources of information such as the internet. Twenty-three 
participants (88.5%) identified their physician, and 15 (60.0%) identified their pharmacist 







Telephone Survey Results 
How well do you understand why you are taking the medications prescribed to you by a 
physician, what the benefits are, and what side effects might occur? 
Level of Understanding N (%) 
Completely 19 (76.0%) 
Somewhat 5 (20.0%) 
Slightly 1 (4.0%) 
Not at all 0 (0%) 






Telephone Survey Results 
Where would you say you get the information you need about medications you are 
taking? 
Source N (%)* 
Physicians 23 (92.0%) 
Pharmacists 15 (60.0%) 
Medication Information Sheets 7 (28.0%) 
Internet 3 (12.0%) 
Other** 2 (8.0%) 
*N = 25; respondents could select more than one category 
**Other included family members, and a physician‟s desk reference 
 
When asked to explain the reasons for their current level of understanding and 
confidence, a high degree of variability in answers was observed. Four participants 
(16.0%) indicated that taking the medication for a long time contributed to their 
understanding and confidence, three participants (12.0%) identified that they had a 
healthcare background, and three (12.0%) indicated that they felt confident in asking for 
help or clarification when they did not understand something. Representative quotes 
included the following: 
“My doctor explains everything and gives me a written report as to why I‟m 
taking them. We discuss why I need them before I start taking them.” 
 
“From the pharmacy standpoint they offer explanations and answer all questions.” 
 






“I‟ve been on it a long time and I know from experience.” 
When telephone survey participants were asked open-ended questions regarding 
their pharmacist‟s role on the healthcare team, 15 (60.0%) participants indicated that 
pharmacists were responsible to counsel patients on side effects, and 14 (56.0%) 
responses related to the pharmacist‟s need to ensure the accuracy of the prescription.  The 
responses were summarized in Table 3. When categorized into dispensing-related 
activities or clinical decision-making or other cognitive function, 25 (47.0%) of 53 roles 
identified by participants related to dispensing activities, and 28 (53%) of the roles 





Telephone Survey Results 
How would you describe the pharmacist‟s primary role or job at the pharmacies you 
visit? 
Role Number (%)* 
Counsel about side effects 15 (60.0%) 
Ensure accuracy of prescription 14 (56.0%) 
Fill the prescription 11 (44.0%) 
Check for drug interactions 9 (36.0%) 
Clinical decision-making 4 (16.0%) 





Telephone survey participants were asked questions related to their level of trust 
and comfort with their pharmacist. Results listed in Table 4 indicated that 92% of 
participants were completely comfortable asking a pharmacist for advice about a 
prescription, 4% indicated that they were somewhat comfortable, and 4% indicated that 
they were slightly comfortable. Furthermore, telephone survey participants were queried 
regarding the factors that impacted their level of comfort and confidence in asking their 
pharmacist for advice, which included questions about what kinds of information they 
would want their pharmacist to know in order to make them more comfortable with 






Telephone Survey Results 
How comfortable would you feel asking a pharmacist for advice about your prescription 
medications? 
Level of Comfort Number (%) 
Completely 23 (92.0%) 
Somewhat 1 (4.0%) 
Slightly 1 (4.0%) 
Not at all 0 (0.0)% 





Table 5 summarizes responses to questions regarding the types of factors that 
affected patient‟s comfort and confidence in asking pharmacists for advice. Thirteen 
participants cited that they have a strong relationship with their pharmacists, which 
helped them feel comfortable. Thirteen participants cited the knowledge-base of 
pharmacists as a key reason they were comfortable with their pharmacist. Factors 
identified by participants that negatively impacted their comfort level in asking 
pharmacists for advice included the observation that their pharmacists appeared to be 
busy, that the pharmacy was not conducive to private conversations about sensitive 
medications. Representative quotes from telephone survey participants included the 
following: 
“Through IHC, because I know them, used them before, and trust them.” 
 
“A lot has to do with how much knowledge they have, the doctor has to know the 
body and function, but there is so much new medication that someone has to be 
up on that just like a doctor is up on treatment and tests and I look to the 
pharmacist for that.” 
 
“Availability, sometimes they are just busy.” 
 
“Sometimes if a medication that is kind of sensitive, I‟d just as soon not have it 
blurted all over. There is no way that they can very quietly say what you need to 
do with it. Sometimes it is a little embarrassing when there are people standing 
behind you.” 
 
Telephone survey participants were asked several questions regarding their 
comfort-level with pharmacist-directed care. Investigators queried patients regarding 
their level of comfort with pharmacists choosing medication regimens, viewing patient 
medical records, ordering laboratory testing, and other functions necessary to these 
processes. When asked about how comfortable participants would be if their doctor asked 





diagnosis, 10 (40.0%) telephone respondents stated that they were completely 
comfortable, nine (36.0%)responded that they were somewhat comfortable. 
Telephone survey participants were asked about their comfort level with having a 
pharmacist choose the best medication for them at the request of their doctor. Table 6 
summarizes participant responses. Nineteen respondents were either completely or 









Telephone Survey Results 
Factors that affect patient‟s comfort and confidence in asking pharmacists for advice 
Factor Number (%)* 
Relationship with pharmacist 13 (52.0%) 
Knowledge-base of pharmacist 13 (45.0%) 
Pharmacist availability 2 (7.0%) 
Sensitivity of information 1 (3.0%) 
*N = 25; respondents answered this question without prompted categories. Categories 






Telephone Survey Results 
How comfortable would you feel if your doctor asked a pharmacist to choose the best 
medication for you based on your medical history and diagnosis? 
Level of Comfort Number (%) 
Completely 10 (40.0%) 
Somewhat 9 (36.0%) 
Slightly 4 (16.0%) 
Not at all 1 (4.0%) 




When telephone survey participants were asked to explain the reasons for 
answering the way that they did, comments were either supportive or unsupportive of the 
concept of pharmacists choosing the best medication for patients. As responses were 
analyzed, the reasons (either supportive or unsupportive) were grouped into themes. The 
first theme related to the clinical knowledge and skill of the pharmacist. Eleven 
comments (44.0%) were supportive of the concept that pharmacists have adequate 
clinical knowledge to choose the best medications for patients, and three (12.0%) were 
unsupportive. Representative quotes included 
Supportive 
“There are so many different drugs out on the market… I think that pharmacists 
know the same information with regard to medication as doctors.” 
 
“They went to school for six years to learn it. If he is a good pharmacist he is 







 “A pharmacist doesn‟t know blood tests and x-rays and all that stuff, a lot goes 
into it.” 
 
“Because the doctor is supposed to know what he is doing more so than the 
pharmacist.” 
The second theme identified related to the pharmacist-patient relationship, and 
explored the impact of this relationship on patient‟s overall trust and comfort level with 
pharmacists choosing medications on behalf of the patient‟s physician. Five comments 
(20.0%) were supportive and five (20.0%) were unsupportive. Representative quotes 
included: 
Supportive 
“I am comfortable with my doctor and with my pharmacist, and I trust them.” 
 
“If I knew him well enough. I happen to know the one at IHC.” 
 
Unsupportive 
“The pharmacists don‟t know me or my situation, and they just rely on the 
doctors.” 
 
“I don‟t know if I have that relationship with my pharmacist.” 
Participants also cited concern related to the pharmacist‟s scope of practice. Four 
comments (16.0%) were supportive of this concept in citing that it was the pharmacists‟ 
“job” to assist with medication selection. Ten comments (40.0%) were unsupportive in 
that they felt that this task should be reserved for their doctor. Representative quotes 
included: 
Supportive 






“That is their business and that is what they do.” 
 
Unsupportive 
“I think the doctor should be aware of what‟s going on with the medications and 
it‟s not necessarily the pharmacist‟s job to do that.” 
 
“Well I expect the physician to know that.” 
The last theme identified in this line of questioning related to how integrated the 
pharmacist was on the healthcare team and how much the pharmacist understood 
regarding a patient‟s medical history. These comments did not convey support or a lack 
of support, but rather stated concern on behalf of the participants. Representative quotes 
included 
“He would have to have my complete medical history and genetic background.” 
 
“The physician needs to have a big part in it also and not just leave it up to the 
pharmacist. I don‟t think the pharmacy has my complete medical history.” 
 
Participants were asked additional questions relating to the type of information 
that pharmacists should have access to if they were to assume a larger role in designing 
medication therapy regimens. The responses were summarized in Table 7. When asked 
whether participants believed that their current pharmacists knew enough about them to 
be able to give good advice and recommendations about medications, the majority of 
participants (76.0%) indicated „yes.‟  When asked if they would be more comfortable 
with a pharmacist choosing the best medication for them at their doctor‟s request if that 
pharmacist had access to their medical records, the participants were fairly evenly split- 
about half indicating that it would make them more comfortable and about half indicating 







Telephone Survey Results 
Do you believe the pharmacists with whom you currently fill prescriptions know enough 
about you to be able to give good advice and recommendations about your medications? 
Response Number (%) 
Yes 19 (76.0%) 
No 6 (24.0%) 




 Telephone survey participants were asked to state whether they would be more 
comfortable with their pharmacist prescribing their medications if they had access to their 
medical records. Fourteen respondents (56%) stated that they would be more comfortable 
in that scenario, and 11 (44%) stated that they would not be more comfortable. The data 
were summarized in Table 8. 
Telephone survey participants were queried regarding their perceptions of how 
important it was that their pharmacist had access to their medical records, and the results 
are summarized in Table 9. The majority of participants felt as though it would be 
“somewhat” important for pharmacists to have access to the patient medical record. Four 
participants (16%) felt that it would be extremely important, and 6 participants (24%) felt 









Telephone Survey Results 
Do you think you would be more comfortable with a pharmacist choosing the best 
medication for you at your doctor‟s request if that pharmacist had access to your medical 
records? 
Response Number (%) 
Yes 14 (56.0%) 
No 11 (44%) 







Telephone Survey Results 
How important is it for a pharmacist to have access to your medical records? 
Level of Importance Number (%) 
Extremely 4 (16.0%) 
Somewhat 14 (56.0%) 
Slightly 1 (4.0%) 
Not at all 6 (24.0%) 






Participants were then asked to explain why they answered this question the way 
that they did. Upon analysis, three themes were identified relative to why pharmacists 
should or should not have access to patient‟s medical records: optimization of care, 
concerns regarding confidentiality, and questions regarding whether this type of service 
was necessary.  
Among the 10 participants (40.0%) who felt that this type of service had the 
potential to optimize care, a common reason was that the pharmacist could provide a 
„double-check‟ for the physician, as well as answer questions without having to wait for 
another appointment or a telephone call from the physician directly. There were also 
comments relating to the fact that the pharmacist could use this information to assist in 
checking for drug interactions and other duties that are traditionally relegated to 
pharmacists.  
Another theme identified when participants were asked why pharmacists 
should/should not have access to medical records related to concerns regarding 
confidentiality. Five (20.0%) respondents stated that they felt giving pharmacists access 
to this type of information created vulnerability for their privacy to be violated. 
Participants who cited this as a concern felt that access to their personal medical record 
should be limited to their doctor, yet some did state that there may be circumstances 
which would warrant a pharmacist needing to access their record.  
Last, four participants (16.0%) stated that they did not recognize a need for 
pharmacists to engage in these types of services. They felt as though their doctor should 





doctor and the role of their pharmacist. They believed that pharmacists should fill 
medications quickly and accurately, and that should be the extent of their responsibility. 
Demographic Surveys 
Demographic surveys were administered prior to starting each focus group 
session. The purpose of these surveys was to both characterize the demographics of the 
focus groups, and also to investigate medication-related issues that could be quickly 
answered in a quantifiable way. Demographic survey questions related to participant age, 
employment status, type of prescription insurance, and highest level of education. Table 
10 describes the age distribution of the focus group participants. The largest age group 
represented was participants in the 7
th
 decade of life. 
Participants most commonly identified themselves as „retired, not working‟, 
which is to be expected given the age distribution shown in Table 11. Approximately 
37% of the participants identified themselves this way. The second most common 
employment status was participants who worked full-time.  
Focus group participants were queried regarding prescription drug benefits, and 
the results are summarized in Table 12. The majority of participants (52.6%) indicated 
that they have a commercially-provided prescription benefit. Approximately 29% of 
participants indicated that they had Medicare Part D. It is unknown whether participants 
with Medicare Part D coverage identified with a commercial plan that manages the 
Medicare Part D benefit. 
Participants were also asked to indicate the highest level of education that they 





indicated that they had received some college, and the highest degree earned was a high 
school diploma in approximately 60% of participants. 
Two questions were asked regarding the type of pharmacy used by participants. 
Participants were invited to check all types of pharmacies that they use. The types of 
pharmacies used by study participants are summarized in Table 14. Participants most 
commonly used grocery store-based pharmacies, followed by chain pharmacies. 
Approximately 16% of participants currently used Intermountain Healthcare outpatient 
pharmacies. 
Participants were asked to indicate which criteria had been used to select their 
pharmacy. The responses were summarized in Table 15. Participants were invited to 
select as many criteria as necessary. Convenience was cited most commonly (84.2%) as a 
criterion upon which participants chose their pharmacy. The next most common criteria 
cited by participants were insurance company requirements and the pharmacist and staff. 
One question in the survey related to various types of medication problems. 
Participants were asked to indicate whether they had, or had not, experienced any of the 
medication problems listed. Participants were asked to check all experienced that applied. 
The participant-reported medication problems were summarized in Table 16. 
Approximately 50% of patients reported having experienced a bad side effect from 
medication. Approximately 50% reported challenges with remembering to take 
medications as prescribed, and 26% reported challenges with remembering to refill 
medications on time. Difficulty paying for medications was reported in approximately 





Last, a question was asked to assess whether focus group participants were 
familiar with the term „medication therapy management.‟ Responses to this question were 
summarized in Table 17. Thirty-four of the 38 participants indicated that they were not 
familiar with the concept of medication therapy management prior to starting the session. 
Four of the 38 participants were familiar with the term, but did not completely understand 






Demographic Survey Results 
Participant Age Category 
Age Category (years) Number (%) 
18 to 30 0 (0.0%) 
31 to 40 2 (5.2%) 
41 to 50 9 (23.7%) 
51 to 60 7 (18.4%) 
61 to 70 14 (36.8%) 
71 to 80 5 (13.2%) 
>80 1 (2.6%) 







Demographic Survey Results 
Participant Employment Status 
Employment Status Number (%) 
Full-time 12 (31.5%) 
Part-time 3 (7.8%) 
Not employed 7 (18.4%) 
Retired, not-working 14 (36.8%) 
Retired, working 2 (5.3%) 
Total 38 (100.0%) 
 
   
 
Table 12. 
Demographic Survey Results 
Participant Prescription Insurance Type 
Insurance Type Number (%) 
Commercial 20 (52.6%) 
Medicare Part D 11 (28.9%) 
Medicaid 1 (2.6%) 
Discount Cards 1 (2.6%) 
No insurance 5 (13.2%) 






Demographic Survey Results 
Participant Highest Level of Education 
Education Level Number (%) 
Some High School 1 (2.6%) 
High School Diploma 8 (21.0%) 
Some College 15 (39.5%) 
Associate‟s Degree 4 (10.5%) 
Bachelor‟s Degree 7 (18.4%) 
Graduate Degree 3 (7.9%) 





Demographic Survey Results 
Types of Pharmacies Used by Participants 
Pharmacy Type Number (%) 
Intermountain Healthcare Pharmacy 6 (15.8%) 
Grocery-store Based Pharmacy 25 (65.8%) 
Chain Pharmacy 13 (34.2%) 
Mail-order Pharmacy 13 (34.2%) 
Other 0 (0.0%) 






Demographic Survey Results 
Factors Contributing to Choice of Pharmacy 
Factor Number (%) 
Convenience 32 (84.2%) 




Physician Referral 2 (5.3%) 
Personal Referral 4 (10.5%) 


















Demographic Survey Results 
Please indicate if you have experienced any of the following. 
Experience Number (%) 
Bad side effect 19 (50.0%) 
Forgetting to take medication 19 (50.0%) 
Difficulty paying for medication 16 (42.1%) 
Forgetting to refill medication 10 (26.3%) 
Left doctor‟s office with questions 
unanswered 
8 (21.1%) 
Difficulty get doctor‟s office to call back 8 (21.1%) 







Demographic Survey Data 
Participant Familiarity with „Medication Therapy Management‟ 
Familiarity Level Number (%) 
Not Familiar at All 34 (89.4%) 
Somewhat Familiar 4 (10.6%) 






Four focus groups were held after telephone interviews were conducted, with 
eleven, nine, ten, and eight participants in the sessions. Participants were queried 
regarding challenges and issues with medications and overall pharmacy experience. 
Additionally, a pharmacist provided a brief description of medication therapy 
management (medication check-up) and collaborative drug therapy management 
(medication team). Focus group participants were asked to give their reactions to these 
concepts, and share any questions or concerns that they could think of during the session. 
Most participants readily spoke out, and in cases when a participant remained quiet, the 
focus group facilitator called upon him/her to share any comments.  
Focus group participants were able to quickly give examples of challenges that 
they experienced with their medications and overall pharmacy experience. Responses 
were similar across all four sessions, and a total of four themes were identified: lack of 
effective communication, the pharmacist/patient relationship, medication pricing, and 
coordination of care.  
Lack of Effective Communication 
Participants expressed a need to communicate more explicitly with pharmacists. 
A number of examples were given to illustrate this concept. In three of the four sessions, 
participants stated that they relied significantly on the medication information sheets that 
were given when a medication was dispensed. While it was perceived as a convenience to 
have this, participants expressed frustration with the small font size which made 





information. Participants also felt as though medication information sheets should contain 
less information, and should be more specific to their individual concerns. While 
participants expressed concern regarding the amount and level of detail that existed on 
medication information sheets, participants in two of the four sessions felt as though 
pharmacists did not give any better information.  
Another example given to illustrate the need for more explicit communication 
was that some participants had experienced side effects or adverse events related to a 
medication, but they had not been warned or counseled to monitor for any side effects. 
They expressed disappointment that their pharmacist had not communicated that to them. 
Conversely, some participants who had received this type of counseling appreciated this 
service. 
Participants also discussed the need to be made aware of changes in their 
medications. Examples included dosage form changes when switching between generic 
manufacturers, insurance changes, and new information that was available regarding their 
medications. Several participants described feeling anxiety when the dosage form of their 
medication did not appear the same as it appeared in the past. They had not always 
received counseling about this and were not sure why this occurred. Additionally, when 
co-payments changed, they did not understand why that change occurred, and would have 
appreciated an explanation. Participants also expressed interest in having their pharmacist 
explain new information that becomes available about their medications. One participant 
described his experience with a Cox-II inhibitor that was withdrawn from the market due 
to safety risks. He was not aware of any safety concern until he could no longer get the 





would improve their overall pharmacy experience as well as understanding of their 
medications. 
Patient/Pharmacist Relationship 
Some participants cited a positive relationship with their pharmacist, but the 
majority stated that they did not maintain any relationship with their pharmacist. Several 
participants stated that they used mail-order pharmacies, which was not conducive to a 
relationship with a pharmacist. Of the participants who stated that they have a positive 
relationship with their pharmacist, they agreed that they found it valuable and stated that 
they would change pharmacies in order to maintain the relationship, if necessary. Of the 
participants who did not have a positive relationship with their pharmacist, a variety of 
reasons were given to explain this. Some participants perceived that the pharmacist was 
too busy to be able to spend time getting to know them. When there were other patients 
waiting for their medications and the pharmacy appears busy, they did not feel 
empowered to ask for the pharmacist‟s time to help with questions or concerns. Another 
factor that impacted the patient/pharmacist relationship was the perceived high turnover 
rate of pharmacists. Participants stated that they often see a new pharmacist each time 
they have their prescriptions filled, which limited their ability and initiative to form a 
relationship. 
Price 
Participants cited a variety of challenges related to pricing of medications, 





medications have different co-payments and prices between pharmacies. Participants 
stated that it was difficult to understand why there was such a large variation in pricing 
for similar medications. Other participants felt it was important for pharmacists to make 
them aware when a generic medication was available so that they could choose if they 
would like to receive the brand or the generic formulation. Several participants described 
situations in which their pharmacist identified a less expensive alternative and worked 
with their prescriber to change the prescription. These participants appreciated this effort, 
but many participants expressed concern that they did not always know what the best 
price was for a medication or how to go about getting the best price.  
In two of the four focus groups, the topic of patient assistance programs was 
addressed. Participants perceived that there were programs available to assist them in 
applying for financial assistance for their medications, but they did not know how to 
access the programs. Participants felt as though the pharmacist or other pharmacy 
employee could help them navigate this process. 
Coordination of Care 
Several participants in all four focus group sessions discussed challenges that they 
had experienced related to coordination of care. The most prevalent challenge identified 
occurred when a pharmacist could not or would not fill a prescription based on insurance 
issues or clinical concern. When the pharmacist had to wait for the physician to clarify 
the prescription or to discuss an issue related to the therapy, it slowed down the process 





 Additionally, participants described challenges related to multiple physicians 
prescribing medications without each of them knowing all of the medications that 
patients were taking. Participants generally agreed that the process of medication review 
and insurance eligibility to should be streamlined so that it did not result in a disruption 
of their care or obtaining medications.  
Participants expressed challenges and concerns related to their medications and 
their pharmacy experience. Participants cited a need for more clear and effective 
communication between themselves and their pharmacist regarding medication 
information. Participants also expressed a need to develop stronger relationships between 
patients and pharmacists. Last, participants expressed difficulty affording and 
understanding of the pricing structure of medications, and challenges with coordinating 
care between their pharmacy and their prescriber.  
Reactions to the Concept of Medication Therapy Management 
Focus group participants were asked to discuss the concept of medication therapy 
management and share their opinions regarding potential benefits, potential drawbacks, 
and overall feasibility. In order to familiarize participants with the concept of medication 
therapy management, a pharmacist gave a brief presentation regarding this concept 
(appendix E). This concept was described as a „medication check up‟ in order to more 
accurately describe the visit in terms that patients could identify with easily. Upon 
hearing the description of a „medication check up‟, participants were asked to share their 





concept of medication therapy management were positive, concerns and questions were 
raised throughout all four focus group sessions regarding cost and other logistical issues.  
Positive comments reflected the potential benefits of this type of service. The 
majority of comments related to the actual medication information that could be relayed 
in this type of session, and acknowledgement that physicians and other practitioners may 
not have time or knowledge base to adequately describe medications or answer patient 
questions. Concerns were raised regarding the overall feasibility of medication therapy 
management related to the costs of the service, as well as other logistical concerns 
regarding the expected frequency of this type of visit, and potential liability issue. 
Medication Information 
Among the majority of participants who felt that a medication checkup session 
would be valuable, the most common potential value cited was that it would be an 
opportunity for patients to learn about drug interactions, side effects, and risks associated 
with medications. Participants generally agreed that this type of information was 
important to understand, and they did not see a current mechanism through which to gain 
this information. Throughout the focus groups, participants gave examples of instances 
where a „medication check-up‟ would have been beneficial. One participant gave the 
following example 
I think this kind of communication is wonderful…. Especially [in someone] who 
was seriously ill. This would be a good thing because I watched them throw drugs 
at my husband… he was taking so many things and if somebody would have sat 
down with us at certain points, cause he was seeing so many different doctors, 







Participants in two of the four focus group sessions discussed the value in 
reviewing regimens to identify and meet patient-defined goals. This concept was 
described in the presentation that was given by the pharmacist, and participants in those 
two sessions agreed that there was potential to both save money and simplify regimens. 
Participants in these two sessions also felt that, while this service might cost money in the 
short-term, it would likely save money in the long term by avoiding drug interactions and 
by choosing medication regimens that would cost them and their insurance company less 
money.  
Physician Time and Knowledge Base 
Another comment that was made in two of the focus group sessions was the 
perception that physicians and other prescribers do not always have the time or 
knowledge necessary to review medications and answer questions regarding medication 
therapies. Participants described feeling rushed by the fact that the physician or prescriber 
often ran late, and they did not feel as though they should ask additional questions. One 
participant gave the following example 
The doctors are so busy, though. Sometimes you don‟t even think of it until you 
go home to ask a specific question, or you feel a little rushed because they‟re 
already 15-20, or 40 minutes late for your appointment. 
 
While time demands on physicians or other prescribers was cited as a deterrent 
from asking questions, participants in all four focus group sessions acknowledged that 
physicians may not have the same level of knowledge regarding medications, drug 





pharmacists are highly trained as medication experts; however, the actual level of training 
that pharmacists received was called into question in two of the four focus groups. 
Cost of Service 
Cost concerns were cited by two participants (5.2%) in two separate focus groups. 
The primary concern in both participants who raised this issue is that this kind of service 
may increase the expense associated with visiting the doctor, or that it may increase the 
overall cost of healthcare delivery. A quote from one participant was 
I don‟t think it will work. It will cost more. I think we‟re all too cost conscience 
right now… So I‟d have to pay double or even $10 more per prescription. I would 
not [do that]. I couldn‟t. 
 
In all focus groups, the facilitator asked participants to express their opinions 
regarding how this type of service should be paid for, and how much they would be 
willing to pay out-of-pocket for a „medication check-up‟. Each focus group gave a 
slightly different response, but the average dollar amount cited by participants was 
between $5.00 and $20.00 as a co-payment. Participants generally agreed that insurance 
companies should pay a standard portion of this kind of service, because they would also 
save money as a result of these sessions. 
Other logistical concerns raised by participants included the expected frequency 
of medication checkup visits. In general, participants agreed that this session should be 
offered as an annual visit, or should be offered when new medications were added. In one 
of the four focus groups, one participant (2.6%) expressed concern over the liability 
associated with having a pharmacist make therapeutic recommendations. The majority of 





patients identified several aspects of care that could be improved by medication therapy 
management services. 
Reactions to the Concept of Collaborative Drug Therapy Management 
In each of the focus group sessions, participants were asked to give their reactions 
to the concept of collaborative drug therapy management, which was referred to as a 
„Medication Team.‟ The pharmacist described this model as a physician, pharmacist, and 
patient working together in a collaborative way so that certain aspects of a patient‟s care 
could be primarily managed by a pharmacist. In this model, the pharmacist would choose 
the best medication for a patient based on their medical conditions, laboratory 
information, and insurance information, and then follow-up with the patient over the 
long-term to make sure that the medication was effectively meeting the patient‟s goals. 
Examples used to describe this model were lipid management and anticoagulation 
management. 
Participant reactions to the concept of collaborative drug therapy management 
included both positive comments and negative comments. Potential benefits of this model 
cited by participants included the perception that collaboration between physicians and 
pharmacists would produce better therapeutic recommendations, as well as the perception 
that pharmacists may be more accessible than physicians. Participants posed questions 
and concerns related to how this may impact the physician/patient relationship and the 
perception that pharmacists may breach the confidentiality of patients‟ medical record. 
Participants in each of the four focus groups expressed that they may feel the necessity to 





Benefits of Collaboration/Accessibility 
Participants in each of the four focus groups described a potential benefit of 
collaborative drug therapy management as value in the pharmacist working along with 
the physician to optimize medication therapy regimens. Representative quotes included 
I think two brains are better…. Doctors can‟t be experts in everything. They think 
they are, but they are not. Where a pharmacist, they‟re specialized to the 
prescription, the drugs, the dosing. 
 
I think, probably, it‟s a good idea for doctors and pharmacists to work together… 
Doctors are human, too. 
 
Participants identified this type of model as a potential mechanism to solve and resolve 
medication problems in a more efficient way than the current model of the community 
pharmacist calling or faxing the physician‟s office and waiting for a physician to call the 
pharmacy back. 
Another potential benefit of this type of service was the perception that 
pharmacists are more accessible than other prescribers, which may benefit patients who 
have outstanding questions or concerns related to their medications. Pharmacist 
accessibility was described by two of the four focus groups and was not further 
discussed. 
Impact of Physician/Patient Relationship 
One concern posed in each of the focus groups was how this type of practice 
model would impact current physician-patient relationships. Participants raised concerns 





physician-patient relationship as well as the overall level of care. Six participants raised 
this concern. Representative quotes include 
When I was prescribed something by a pharmacist, I would go to my physician 
and say, okay, this is what he said to do. Is it okay? 
 
I‟d go back and check with my physician, or [would want] an email to me saying 
that he agreed. Something concrete. 
 
Participants questioned how communication would occur between the physician and 
pharmacist in this setting, but agreed that this type of model would pose a risk of losing 
communication between the pharmacist and physician as well as a risk of comprising the 
physician-patient relationship. 
Confidentiality of Patient Information 
A concern regarding the potential for confidential records to be breached was 
raised in three of the four focus groups. Participants recognized that sensitive information 
would need to be disclosed to pharmacists in order for collaborative drug therapy 
management to be effective. Some participants stated that this would be concerning, and 
when probed further, participants in two of the four focus groups stated that they were 
less comfortable with pharmacists viewing their medical records or other sensitive 
information because the pharmacy was less private than their physician‟s office. They 
may also see a different pharmacist each time they visit the pharmacy. Representative 
quotes included 
The other [concern] is the turnover in the pharmaceutical offices, you might meet 
one pharmacist and then a few months down the road… oh where did they go? 
 






In general, the portion of time spent discussing questions and concerns related to 
collaborative drug therapy management was larger than the amount time spent discussing 
potential benefits. Participants cited more concerns related to collaborative drug therapy 
management than to the concept of medication therapy management.  
Overall Themes Identified 
Data gathered in the telephone surveys as well as focus groups and demographic 
surveys were analyzed using grounded theory methodology described in Chapter III. 
When data gathered from telephone interviews, demographic surveys, and focus groups 
were analyzed together, two over-arching themes were identified. First, focus group 
participants identify a need for improved understanding of medications and medication-
related issues. Second, participants reacted positively to the concepts of medication 
therapy management and collaborative drug therapy management. However, a number of 
questions and concerns were identified by participants that may affect patients‟ trust in 
these pharmacist-provided services. 
Need for Improved Understanding 
The need for improved understanding of medications and medication-related 
issues was explored in greater detail during the focus group sessions than in the telephone 
surveys. However, the demographic surveys corroborated the discussions that occurred in 
the focus groups in that a large number of focus group participants reported experiencing 
a medication-related frustration or challenge (Table 17). The most commonly cited 





side-effects and drug interactions. Some focus group participants stated that sources of 
information that they had used were not adequately tailored to their individual needs, and 
were often difficult to understand and interpret.  
Additionally, participants cited challenges with coordinating care among their 
prescribers, and described frustration when lapses in care coordination resulted in their 
inability to attain their medications. Participants also felt that it was difficult to make sure 
that each of their prescribers knew of their other medications when they received new 
prescriptions. Responses of this nature were observed primarily in the focus groups. 
Reactions to Pharmacist-Provided Clinical Services 
Participants‟ attitudes and reactions to the concept of pharmacists playing a more 
clinical role in patient care were assessed in telephone interviews as well as focus groups. 
Telephone interview questions explored patients‟ underlying impressions of pharmacists 
in terms of medication-related knowledge. Focus groups were designed to provide 
participants some insight into how these services might look and what patients could 
expect to gain as a result of participating.   
Telephone survey participants indicated that pharmacists were a major source of 
medication-related information currently, and that pharmacists were viewed as having 
both dispensing and clinical-decision-making responsibility. When asked how 
comfortable they would be asking a pharmacist for medication-related advice, 
participants were generally very comfortable with that concept. The majority of 
participants were also comfortable with having a pharmacist select the best medication 





Focus group participants were generally supportive of the concept of visiting one-
on-one with a pharmacist for a “medication check-up”. While reactions to the 
collaborative drug therapy model were more guarded, most respondents recognized the 
potential value to this type of service. 
A number of questions and concerns regarding these two models were identified 
in the telephone interviews, and then confirmed and further explored in the focus groups. 
Participants expressed concern regarding the privacy of their personal medical record 
should their pharmacist be able to access it in the pharmacy. The reasons cited for this 
were that the pharmacy does not “feel” secure, that they usually see different pharmacists 
each time they visit the pharmacy, and that there are usually other patients in the same 
area. 
Another concern cited by participants was the potential for errors to occur due to a 
lack of communication between providers. Several participants stated that if their 
pharmacist were to change therapy, they would want to check with their referring doctor 
prior to implementing the recommendation of the pharmacist. When explored further, this 
was due to a number of factors including a lack of a long-standing relationship with their 
pharmacist, as well as not trusting that proper communication would occur between the 
pharmacist and the referring provider. 
The attitudes and perceptions of patients regarding pharmacist-provided clinical 
services were generally positive. The two data collection methods allowed for the 












The primary objective of this thesis was to characterize patient attitudes and 
expectations regarding pharmacist-provided clinical services in the outpatient pharmacy 
setting. The combined methodologies of telephone surveys, demographic written surveys, 
and focus groups yielded data that will allow for this characterization, as well as an 
understanding of the underlying assumptions that may have contributed to these attitudes.  
 As the profession of pharmacy prepares to more fully integrate pharmacist-
provided clinical services in the outpatient setting, it is important to include the desires 
and preferences of patients. It is also important to understand current challenges that 
patients experience related to their medications so that programs can be designed to solve 
patient-identified problems with pharmacy services.  
Need for Improved Understanding 
 This sample of patients was able to articulate a number of areas of frustration with 
their medications and overall pharmacy experience. The majority of problems identified 
and discussed in both telephone interviews and focus groups may be addressed by 
increased communication between pharmacists and patients. A number of barriers exist 





Communication is often facilitated by a strong relationship between provider and patient, 
and participants stated in both the telephone surveys and focus groups that they valued 
relationships that developed over time with other healthcare practitioners, especially 
physicians. Patients did not perceive relationships with their pharmacist to the same 
extent that they perceived relationships with physicians. Many times patients stated 
preferring a „pharmacy‟ and not a particular pharmacist. In order to engage patients in 
increased communication, it will be important to consider how to facilitate positive 
relationships between pharmacists and their patients. 
 Focus group participants who explicitly stated frustrations related to a lack of 
communication stated that they would have benefited from information that, under an 
ideal model of pharmacy practice, would have been communicated with patient 
counseling as described in OBRA90. For example, patients reported frustration with 
experiencing side effects that they had not been warned about, and also reported 
frustration when their medication dosage changed without being made aware of the 
change. This demonstrated that either patient counseling has not met the intent of 
OBRA90, or that despite the efforts of pharmacists to counsel patients, the message is not 
being clearly received by patients.  
This sample of patients also reported experiencing the consequences of poor 
communication and education regarding medication therapy. Approximately half of focus 
group participants reported experiencing a bad side effect of a medication, and would 
have expected to know about the potential side effects prior to taking the medication. 





medication safety issues that were reported in the media but not addressed by their 
pharmacist.  
These negative experiences may impact patient adherence to medication 
regimens, which could have significant clinical and economic consequences. These data 
showed not only that overall communication improvements between pharmacists and 
patients are needed, but it also highlighted some specific areas of priority from the 
perspective of patients who use multiple chronic medications.  
Reactions to Pharmacist-Provided Clinical Services 
Focus group participant responses to the concept of medication therapy 
management described as a „mediation check-up‟ were consistently positive. Participants 
easily identified the opportunity to address many of their concerns using a session similar 
to what the pharmacist described during the focus group session. While patients did not 
initially consider their pharmacist as a member of their healthcare team, comments 
indicated that there was opportunity for patients to benefit from a pharmacist being 
engaged in their care. Participants also responded favorably to the idea of creating a 
medication list that included all medications and supplements, allergies, disease states, 
and emergency contact information. The creation of this list was considered one of the 
core elements of medication therapy management services, and based on participant 
response to this concept, was one of more valuable aspects of a medication therapy 
management session. 
The idea of a pharmacist taking on a leadership role within the healthcare team 





healthcare payers was met with positive reactions. This concept was described as “the 
pharmacist working on behalf of the patient with other healthcare practitioners to design 
a medication regimen that was tailored specifically for that patient.” The session was 
described as an opportunity for patients to describe their goals of medication therapy (i.e., 
lowest cost regimen, simplified regimen, regimen, etc.), and have a pharmacist work with 
other providers to meet those goals. Participants did not initially perceive this process as 
being viable until the pharmacist explained examples of how regimens could be modified 
to meet patient-specific needs. Upon hearing a few examples of medication regimen 
changes that could potentially result from this type of session, participants were much 
more enthusiastic about this opportunity.  
Another concept that emerged in these discussions was related to increasing the 
clinical role of community pharmacists. Participants identified themselves with a 
pharmacy, rather than a pharmacist. Yet, they identified with their physician, and not 
necessarily their clinic or physician‟s office. This finding was significant in that it 
demonstrated that participants do not currently perceive that their pharmacist is engaged 
with them over time. Many of the benefits that pharmacist-provided clinical services 
could bring on the part of patients are dependent on a trusting relationship that is built 
over time. Efforts to build the relationship between patients and pharmacists may impact 
the readiness that patients have to participate in these types of services. 
In summary, most participants were not currently realizing the full benefit of a 
pharmacist participating in their care beyond that of medication dispensing and basic 





fact that patients were not aware of benefits that pharmacist-provided clinical services 
could add.  
An interesting finding was that many of the positive comments were related to the 
concept of medication therapy management, that when deconstructed, were benefits that 
patients could expect to gain from medication counseling. For example, participants 
found value in learning about potential side effects of medications and the interactions 
between over-the-counter medications and some prescription medications. This reflects 
both a validation that patient counseling is an essential component of medication 
dispensing, as well as an indication that this type of patient counseling is not consistently 
delivered in an effective manner.  
 Study participants in telephone surveys as well as focus groups generally trusted 
pharmacists‟ knowledge and expertise related to medications. However, the extent to 
which they would trust pharmacists to assume more decision-making responsibility 
related to medication regimen design, patient monitoring, and patient education was 
related to a number of factors, including the design of the program, communication 
between referring physician and pharmacist, pharmacists‟ clinical knowledge, and the 
design of the pharmacy. Further research is needed to fully understand whether patients 
would trust pharmacists this capacity.  
 An interesting factor that contributed to participant reservations regarding 
collaborative drug therapy management was the security of patients‟ confidential medical 
information. Participants expressed concern that their private medical information would 
be seen by practitioners other than their physicians. When asked to describe their concern 





information remaining private. For example, a busy pharmacy with many patients in the 
lobby or waiting area where no private consultation area exists would not be considered 
an appropriate venue for private medical information to be viewed and used in patient 
education.  
 Pharmacists and pharmacies providing clinical services in the outpatient 
pharmacy setting should consider these data as they plan and execute these services. 
Business and clinical practice models should address the major questions and concerns 
that were identified by this sample, which may reflect a patient population that stands to 
benefit most from these services. Focus should be placed on building long-term 
relationships between pharmacists and patients, communicating and educating patients 
regarding the clinical knowledge-base and expertise of pharmacists, and building 
communications infrastructure whereby frequent communication may occur between 
pharmacists, referring physicians, and patients.  
Study Limitations 
 It is important to consider the patient population that was represented by 
participants of telephone interviews and focus groups, and apply their reactions and ideas 
in the appropriate context. Potential participants were patients of Intermountain 
Healthcare, an integrated healthcare delivery system in Utah. Patients were asked to 
participate if they had been prescribed at least four chronic medications. The pharmacy 
that patients used to fill prescriptions was not considered in the inclusion criteria.  
Participants were selected based on these criteria, because it was presumed that 





pharmacists than other patient populations. Additionally, the sample of participants used 
in this study reflected the criteria used by health insurance programs and Medicare Part D 
providers that currently offer reimbursement for pharmacist-provided clinical services, 
such as medication therapy management. Data collected and themes identified in this 
thesis may be utilized in the design and implementation of pharmacist-provided clinical 
services that are tailored to meet the needs of similar patients, but may not necessarily 
reflect the expectations of other patient types.  
This study was limited by the small sample size of both telephone participants and 
focus groups. A larger sample size would have increased the ability of these data to be 
generalized to broader patient populations. Additionally, the group of participants was 
relatively homogenous. The decision was made to query this population because it was 
understood that this population would most likely benefit from pharmacist-provided care 
in the outpatient setting. However, other important groups of patients and pharmacy 
customers were not included in this study. For example, patients who use pharmacy 
services infrequently will likely have a distinct set of attitudes and expectations about 
their overall pharmacy experience and a different attitude regarding medications in 
general. Questions regarding the occupation of study participants were not asked in the 
telephone surveys or the focus group sessions. Participants with backgrounds in 
healthcare delivery may have provided different responses than those without healthcare 
backgrounds.  
 This study was conducted within an integrated delivery network. Implicit 
assumptions in the models that were posed included an interoperable medical record and 





healthcare practitioners. Outpatient pharmacists continue to struggle to gain access to 
these kinds of information, and may not be able to provide the same level of service as 
was described to study participants in all outpatient pharmacy settings.  
 The majority of participants in the telephone surveys and focus groups generally 
did not describe strong relationships with their pharmacists. It is unknown what impact 
this may have had on participant responses to the survey questions and concepts 
described in the focus group sessions. Patients who have a positive relationship with their 
pharmacist currently may perceive more or less value from these kinds of services than 
patients who do not have a positive relationship with their pharmacists. This study could 
have explored this concept further by grouping focus group participants by their 
perception of their current relationship with their pharmacist.  
Another limitation of this study was the low quality of audio-recording that was 
recovered from the session. The ambient noise in the room and the limitations of the 
recording equipment made the recordings difficult to dictate directly. The investigators 
utilized these audio-recordings in addition to notes taken during the session to compile 
patient comments.  
Finally, a pharmacist was present during the focus group sessions. This may have 
had an impact in the responses of the focus group participants in an immeasurable way. 
In order to minimize the impact that the presence of a pharmacist might have brought, the 
focus group facilitator (nonpharmacist) led the meetings, and the pharmacist only spoke 
to give the participants brief presentations. The pharmacist did not answer questions 






Future efforts within the profession should focus on elucidating differences 
between patient counseling and medication therapy management services, as well as 
differentiating patient-preferred educational modalities. While most healthcare 
stakeholders understand the importance of proper patient counseling for medications, the 
process has not been successfully implemented throughout all medication dispensing 
models. Given the fact that proper education has the potential to reduce medication errors 
and increase compliance in the outpatient setting, work of this nature is essential as 
pharmacy continues address the need for adequate patient education.  
Additional research is necessary to determine adequate reimbursement rates for 
pharmacist-provided clinical activities in the outpatient setting. The misalignment of 
clinical goals and reimbursement models may be a major contributing factor to the 
current challenges in educating patients. Specifically, additional research is needed to 
explore the true costs of delivering medication therapy management or other patient 
education as well as the financial impact of these services on overall health expenditures.  
This thesis characterized patient attitudes regarding pharmacist-provided clinical 
services delivered in the outpatient setting. Additional research that explores both 
physician attitudes and pharmacist attitudes is also needed. As pharmacists take on more 
clinical responsibility, collaboration and communication between healthcare providers 
becomes increasingly important. Further exploration into the needs and expectations of 
pharmacists and physicians is necessary to ensure that efforts to grow these services will 






In conclusion, the population studied experienced a variety of medication-related 
and pharmacy-related challenges. Participants studied also expected to receive accurate 
and pertinent information about their medications, but they did not necessarily look to get 
this information from pharmacists. Sources used to gather medication-related information 
included pharmacists, but participants cited other means of education to a greater extent 
than they cited pharmacists. When asked to react to the concepts of medication therapy 
management and collaborative drug therapy management, participants responded 
favorably to medication therapy management, and maintained some reservations and 
concerns regarding the concept of collaborative drug therapy management. The data 
collected in this thesis may provide insight into how patients experienced the pharmacy 
and what they expected from their pharmacist. This information can inform strategic 
planning for community pharmacies, especially in an integrated delivery network 




















Patient Perceptions of Pharmacist-Provided Services  
within Intermountain Pharmacies 
Interview Script 
 
Hi.  This is (interviewer name) calling on behalf of Intermountain Healthcare‟s Strategic 
Planning and Research Department.  We conduct market research that assists 
Intermountain Healthcare in providing better services for our patients. May I speak with 
(patient name)? 
 
If asked why calling: 
I‟m calling to invite (patient name) to complete a brief interview about some important 
healthcare issues. 
 
If worried that it is not a legitimate call:  I am one of the telephone interviewers 
employed by Intermountain Healthcare‟s strategic planning and research department.  
Since we do a lot of our interviewing in the evening and weekend, we often call from our 
homes.  If you‟d like to speak with the Senior Researcher at Intermountain in charge of 
the study, I‟d be glad to have him call you.  His name is Sean Meegan and his direct line 
at Intermountain is 801-442-3039. 
 
If patient is called to phone: 
Hi.  This is (interviewer name) calling on behalf of Intermountain Healthcare‟s strategic 
planning and research Department. 
 
We‟re talking to patients who have prescriptions at an Intermountain Healthcare 
pharmacy about their perceptions of pharmacist services.  Would you consider taking 10 
or 15 minutes to answer some questions?  We‟re offering a $10 Smith‟s gift card as a 
small thank you to people who participate. 
 
If no: 
Ok.  Thanks for your time.  Have a good day/night. 
 
If later, set callback. 
 
If yes, or begin here for callback: 
Great!  Thanks for your willingness to help out. 
 
Let me assure you that anything we talk about will be completely anonymous and 
confidential.  We‟ll be reporting data at the group level and will never identify a 
particular individual‟s responses. 
 
Screener: 







No  I‟m sorry, but we‟re only doing interviews with recent pharmacy patients at this 
time.  Thanks for your willingness to help out though.  Have a good day/night. 
 
Ok, good.  Let‟s begin 
 
1. How well would you say you understand why you are taking medications that have 
been prescribed to you by a physician, what the benefits are, and what side effects 
might occur with those medications?  Would you say…? 





2. Can you tell me why you rated it that way? (Verbatim) 
 





Literature that came with medication 
Other (specify) 
 
4. Let‟s suppose you had questions or concerns about medications you were taking.  




Literature that came with medication 
Other (specify) 
 
5. How would you describe pharmacists‟ primary role or job at the pharmacies you 
visit?  (Verbatim) 
 
6. Is there anything else pharmacists have responsibility for? (Verbatim) 
 
7. How comfortable would you feel asking a pharmacist for advice about your 
prescription medications?  Would you say…? 











9. What do you think would make you feel more comfortable asking a pharmacist for 
advice about your medications? (Verbatim) 
 
10. How comfortable would you feel if your doctor asked a pharmacist to choose the best 
medication for you based on your medical history and diagnosis?  Would you say…? 





11. And why is that? (Verbatim) 
 
12. And what do you think would make you feel more comfortable with a pharmacist 
choosing the best medication for you at your doctor‟s request? (Verbatim) 
 
13. What do you think would be most important for a pharmacist to know about you to be 
able to give good advice and recommendations about your medications? (Verbatim) 
 
14. Do you believe the pharmacists with whom you currently fill prescriptions know 





15. Do you think you would be more comfortable with a pharmacist choosing the best 





16. How important do you think it is for a pharmacist to have access to your medical 
records?  Would you say…? 
Not at all 
Slightly 
Somewhat, or  
Not at all? 
 
17. Can you tell me why you rated its importance that way? (Verbatim) 
 
That‟s all the questions I had for your today.  Thanks very much for your time.  Before 
we get off the phone, can you tell me the name and address to which you‟d like the 































Personalize by addressing to patient 
 
Intermountain Healthcare will be conducting a research project over the next couple of 
months that examines patients‟ experiences with their pharmacists.  The research will 
benefit patients like you by improving coordination of pharmacy services. 
 
You are eligible to participate in this research study regardless of where you purchase 
your prescriptions. You were chosen as a potential study participant through a 
confidential review of your medical records.  
 
As part of this study, we may call you and ask you to participate in a telephone survey 
about how satisfied you are with your visits at your pharmacy and what you expect from 
your pharmacist when they fill your prescriptions. We may also call you and invite you to 
participate in a focus group. Focus groups involve meeting with several other people and 
a researcher and discussing a particular topic; in this case, the discussion will be about 
what patients expect from their pharmacist.   
 
You are not required to participate in any aspect of the research project. If you do not 
wish to participate, you may simply state that you are not interested in participating when 
you are called by a study coordinator. Neither your doctor‟s office nor your pharmacy 
will know whether you have chosen to participate or not. Also, your answers will be kept 
completely confidential, will never be associated with your name, and will only be 
summarized together with many other participants‟.  
 
All information that has been used to identify you (for example; your name, telephone 
number) will be securely discarded once the study is complete.  
 
If you have any questions, or do not wish to be contacted, please contact Melissa Skelton 






Melissa Skelton Duke, PharmD 
Health-System Pharmacy Administration Resident 
Intermountain Healthcare 
36 South State Street, 17th Floor 
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Department of Pharmacy Services 
 
Outpatient Pharmacy Focus Groups 
Recruiting Script 
 
Hi.  This is (recruiter name) with Lighthouse Research calling on behalf of Intermountain 
Healthcare.  Can I speak with (patient name)? 
 
If asked by someone other than patient why calling:   
We‟re calling with an invitation to participate in a research study. 
 
If asked by patient how information was obtained: 
We are a professional research company and Intermountain Healthcare contracts with us 
to recruit for their focus groups.  They provide us only with names and phone numbers of 
recent patients.  None of your medical information was every disclosed. 
 
If patient wants to talk to someone at Intermountain: 
Sean Meegan is the study coordinator at Intermountain Healthcare.  He would be glad to 
speak with you about any questions or concerns you have.  He can be reached at 801-
442-3039. 
 
If patient comes to the phone: 
Hi.  This is (recruiter name) with Lighthouse Research calling on behalf of Intermountain 
Healthcare. 
 
You might recall recently receiving a letter from Intermountain Healthcare describing a 
research project about pharmacy services.  I‟m calling today to invite you to participate in 
a focus group where you would discuss your experiences with and expectations for 
pharmacy services.  You would also read and complete a short survey in the group.  
We‟re holding 4 focus groups in the evenings starting on Monday, April 19, and would 
provide you with a $50 thank you for participating in one of them.   
 
Would you be interested in participating in one of the groups? 
 
If no: 





We‟ll be holding the groups on Monday, Tuesday, and Wednesday, April 19, 20, and 21, 
and on Monday April 26.  The groups will be held from 7 to 8:30 PM at Intermountain 






On which of those days do you think you‟d be able to attend a focus group? 
 Monday, April 19 at 7 PM 
 Tuesday, April 20 at 7 PM 
 Wednesday, April 21 at 7 PM 
 Monday, April 26 at 7 PM 
 
Excellent.  On… 
(use appropriate description) 
 Monday, April 19, the group will be held at 7 PM in classroom 5 in the Doty 
Education Center at Intermountain Medical Center. 
 Tuesday, April 20, the group will be held at 7 PM in classroom 1 in the Doty 
Education Center at Intermountain Medical Center. 
 Wednesday, April 21, the group will be held at 7 PM in classroom 8 in the Doty 
Education Center at Intermountain Medical Center. 
 Monday, April 26, the group will be held at 7 PM in classroom 3 in the Doty 
Education Center at Intermountain Medical Center. 
 
I‟d like to be able to send you a reminder note, a map, and directions to the group.  Is 
there an email address to which I could send those? 
 
If yes: 
And what is that email address? 
 
If no: 
Ok.  To what address would you like me to mail the reminder note and map? 
 
Great.  I‟ve got you signed up for a focus group on… 
(use appropriate description) 
 Monday, April 19, at 7 PM in classroom 5 in the Doty Education Center at 
Intermountain Medical Center. 
 Tuesday, April 20, at 7 PM in classroom 1 in the Doty Education Center at 
Intermountain Medical Center. 
 Wednesday, April 21, at 7 PM in classroom 8 in the Doty Education Center at 
Intermountain Medical Center. 
 Monday, April 26, at 7 PM in classroom 3 in the Doty Education Center at 
Intermountain Medical Center. 
 
Please try to arrive about 5 minutes early, so the group can get started right on time. 
If for some reason you need to cancel or have any questions about the project, you can 
contact Sean Meegan with Intermountain Healthcare at 801-442-3039. 
 

















Department of Pharmacy Services 
 
Outpatient Pharmacy Focus Group 
Participant Survey 
 
Where do you usually have your prescriptions filled? (check all that 
apply) 
□ Intermountain Healthcare pharmacy 
□ Grocery-store based pharmacy (i.e. Smiths, Albertsons) 
□ Chain retail pharmacy (i.e. Walgreens, RiteAid) 
□ Mail-order pharmacy 
□ Other: Please specify: ___________________________________________ 
 
How did you choose your pharmacy? (check all that apply) 
□ Convenience 
□ The pharmacist and staff 
□ My insurance company told me where to get my medications 
□ I was referred to my pharmacy by my doctor 
□ I was referred to my pharmacy by a family member or friend 
 
What type of insurance do you have to help you with your 
prescriptions? (check all that apply) 
□ Commercial plan from my employer (i.e. SelectHealth, United, Aetna) 
□ Medicare Part D 
□ Prescription discount program (not related to my health insurance) 
□ No prescription benefit coverage 
 
Have you ever heard of ‘medication therapy management’ or a 
‘medication check-up?’ (check one) 
□ No 
□ Yes, but I’m not sure what it means 
□ Yes, and I know what it means 
 
Please indicate if you have experienced any of the following:  
(check all that apply) 
□ I have experienced a bad side effect from a medication. 
□ I have had trouble paying for medication. 
□ I have forgotten to take my medications every day. 
□ I have forgotten to have my medications refilled on time. 
□ I have left my doctor’s office with questions about my conditions or what I am 





□ I have had difficulty getting my doctor’s office to call me back. 
□ I have not understood exactly why I am taking some medications 
What is your employment status? (check one) 
□ Full-time 
□ Part-time 
□ Not employed outside the home 
□ Retired and not working 
□ Retired and working full- or part-time 
 
What is the highest level of education you have completed? (check 
one) 
□ Some High School 
□ High School Diploma 
□ Some College 
□ Associate’s Degree 
□ Bachelor’s Degree 
□ Graduate Degree 
 
What is your age group? (check one) 
□ 18 to 30 years 
□ 31 to 40 years 
□ 41 to 50 years 
□ 51 to 60 years 
□ 61 to 70 years 
□ 71 to 80 years 



















































































Focus Group Guide 
Strategic Planning and Research 
 
 Hello and Welcome 
 Introductions 
o Sean – Senior Researcher, moderator 
o Missy – Pharmacy Resident who will describe some of the pharmacy topics 
we‟ll discuss 
 Purpose and Structure of the Focus Group 
o Consent Forms 
o Purpose – To understand your experiences with and perceptions of some 
unique pharmacy services 
o Brief written survey 
o Brief Discussion 
o 3 Descriptions of Pharmacy Services and Discussions of Each 
 Survey 
 
Let‟s begin by talking about some of your pharmacy and medication experiences.  I‟d 
like you to consider your experiences with pharmacists, pharmacies, prescriptions, and 
dosages and help us understand any issues, challenges, or problems you have had.  Our 
goal isn‟t to identify what one pharmacy or another did wrong.  Rather, our goal is to 
understand any challenges you have experienced in managing medications and what 
might be done to make that easier or more effective for you. 
 
So, what kinds of issues, challenges, or problems have you had in managing your 
medications with a pharmacy? 
 
Ok.  At this point, I‟d like to have Missy provide a general overview of a particular 
pharmacy service and then we‟ll spend a few minutes discussing it. 
 
Description 1 – Medication Check-Up  
Missy 
 
 What would you say are some of the benefits or advantages of this service? 
 What would you say are some of the drawbacks or limitations of this service? 
 Do you think you would use this kind of a service from a pharmacist?  Why or why 
not? 
 What else would you want to know about this kind of service before you‟d use it?   
 What else do you think should be included in this kind of service? 
 
Great.  Now once again I‟m going to have Missy provide a general overview of another 






Description 2 – Pharmacists Helping with Your Care 
Missy 
 
 What would you say are some of the benefits or advantages of this service? 
 What would you say are some of the drawbacks or limitations of this service? 
 Do you think you would use this kind of a service from a pharmacist?  Why or why 
not? 
 What else would you want to know about this kind of service before you‟d use it?   
 
Ok.  Thanks for your ideas there.  I‟m going to ask Missy to provide a general overview 
of just one more pharmacy service and we‟ll wrap up our time together with a discussion 
about that. 
 
Description 3 – Getting the Most Out of Your Trip to the Pharmacy 
Missy 
 
 Do you think you would take advantage of some of these activities when you come in 
to pick up a prescription?  Why or why not? 
 Which of the activities would be most useful or meaningful to you? 
 What other activities or information do you think you would find useful or 
meaningful when you come in to pick up a prescription? 
 
